| Literature DB >> 30687681 |
Stefano Crenna1, Antonio Osculati1, Silvia D Visonà1.
Abstract
The effective control of vaccine-preventable diseases generally requires indefinite maintenance of extremely high rates of timely vaccination. Therefore, vaccine hesitancy is of paramount importance and needs to be addressed. In Italy, regulations about vaccinations are controversial and, to some extent, inconsistent. Even though the childhood vaccinations are mandatory by law (Italian Law n. 891/1939, n. 292/1963, n.51/1966 and n. 165/1991), the limited deterrent effectiveness of the sanctioning system, and the changes introduced by the Italian Constitutional Law n. 3/2001 (devolution of almost all the competences and responsibilities in health matters to the Regions and the Autonomous Provinces), were the fertile ground in which new vaccine policies were generated and developed, radically different from the existing ones: many Regions, based on what was decided in 2005 - on an experimental basis - by the State-Regions Conference, decided to abolish the vaccination obligation and/or to stop the imposition of administrative sanctions on non-compliant parents. In addition, since then, there is a worrying tendency to decline vaccinations due to the parents' mistrust in pharmaceutical companies and health policies. Therefore, recently, the Italian government decided to deploy an emergency ordinance (Italian Decree Law n. 73/2017). In this article, the authors are going to illustrate the current situation in Italy concerning vaccination policy, from a legislative and social point of view.Entities:
Keywords: Vaccines; children immunization; vaccines refusal
Year: 2018 PMID: 30687681 PMCID: PMC6321942 DOI: 10.4081/jphr.2018.1523
Source DB: PubMed Journal: J Public Health Res ISSN: 2279-9028
Comparison between disease-related risks and vaccine-related risks.
| Disease | Disease-related risks | Vaccine-related risks |
|---|---|---|
| Measles | Pneumonia: 1/20; Encephalitis: 1/2000; Death: 1/3,000 | Encephalitis or severe allergic reactions: 1/1,000,000 |
| Mumps | Encephalitis: 1/300 | |
| Rubella | Congenital rubella: 1/4 if contracted at the beginning of pregnancy | |
| Diphtheria | Death: 1/20 | Inconsolable crying followed by complete recovery: 1/100; |
| Tetanus | Death: 3/100 | Convulsions or shock followed by complete recovery: 1/1750; |
| Pertussis | Pneumonia: 1/8; Encephalitis: 1/20; Death: 1/20 | Acute encephalopathy: 0-10.5/1,000,000; Death: unproven |
| Varicella | Incidence: 4000/100,000; Lethality: 4-9/100,000; Hospitalization: 1,3-4,5/100,000; Neurological complications: 0.4-10.1% of hospitalized patients; Pneumonia: 5-14%; Skin superinfections: 36% of hospitalized patients | Varicella-like rash: 3.8%; Pneumonia: <1%; Febrile convulsions: <0.1%; Severe allergic reactions: <0.01% |
| Meningococcal meningitis | Lethality: 10%; Complications: 25% (amputations, skin lesions, hemiplegia, mental retard, epilepsy, neurological deafness, post-traumatic stress disorder, depression, anxiety) | Dizziness: <1/100; Paresthesia, anaphylactic reactions: <1/10,000 |
| Invasive pneumococcal disease (IPD) | Lethality: 15-20% in case of pneumococcal sepsis in adults, 30-40% in case of pneumococcal sepsis in people over 65, 12% in case of pneumococcal meningitis 12%. | Hypersensitivity reactions including facial edema, dyspnea, bronchospasm, convulsions (including febrile convulsions), rash, urticaria or urticaria rash, anaphylactic reactions, angioedema, hyporesponsive-hypotonic episodes, urticaria on the site of injection, itching on the site of injection, hot flushes, apnea in very premature newborns: <1/1,000. Lymphadenopathy (near the site of injection), erythema multiforme: <1 /10,000 |
| Non-invasive pneumococcal disease | CAP mortality: 5-15% in hospitalized patients, 20-45% in ICU patients, 40% in people over 80 | |
| Haemophilus Influenzae infection (HiB) | Lethality: 3-6%. Complications: 20% of patients who survive the Hib meningitis report hearing loss and other neurological sequelae. | Allergic reactions, angioedema, hypotonic-hyporesponsive episodes, convulsions, syncope or vasovagal reactions during injection, drowsiness, apnea, urticaria, rash, extensive swelling of the injected limb, hardening of the site of injection |
| Poliomyelitis | Fever, weakness, headache, nausea, flu-like syndrome, nuchal/spinal rigidity, pain in the limbs: 4-8%. | Local reactions on the injection site (pain, redness, hardening, edema): ≥ 1/10 |
| Hepatitis B | Mortality due to acute hepatitis: 2% Development of a chronic infection: > 30% in children, <5% in adults Complications of chronic infections: liver cirrhosis 25%, liver cancer 5% | Lymphadenopathy, arthralgia, paresthesia, hives, itching and rash: <1/1000. |